On the 16th, domestic bio and pharmaceutical-related stocks showed clear divergence by individual stock. While Daewoong Pharmaceutical, SunBio, and Prestige Biologics rose, Alteogen, Samchundang Pharm, and Samsung Epis Holdings retreated by relatively large margins. Rather than the entire sector moving in one direction, the session was characterized by differentiated trends driven by stock-specific supply and demand differences.

■ Gaining Stocks Daewoong Pharmaceutical closed at 122,800 won, up 3,900 won from the previous trading day, for a gain of 3.28%. During the session, it recorded a high of 126,200 won and a low of 117,900 won. SunBio rose 3.88% to 6,160 won, marking the highest gain among the stocks included in the data. Prestige Biologics also gained 2.79% to 1,845 won, and Aprogen traded up 2.68% at 2,300 won. Hanmi Pharmaceutical climbed 0.65% to 387,000 won, having fluctuated significantly during the session, rising as high as 392,500 won before dropping to 370,500 won. Boryung (0.73%), Green Cross (0.58%), and Dong-A ST (0.15%) also posted modest gains.

■ Declining Stocks Alteogen traded at 276,500 won, down 12,000 won from the previous trading day (a decline of 4.16%). It rose as high as 288,500 won intraday before pulling back to 274,000 won, unable to escape the bearish zone. Samchundang Pharm also fell 4.18% to 183,600 won, opening at 190,200 won and dropping as low as 181,700 won during the session. Samsung Epis Holdings declined 3.71% to 389,500 won, and Ildong Pharmaceutical's related entity ISU Abxis traded down 2.91% at 3,175 won. HanAll Biopharma (down 2.76%, 52,900 won), LG Chem (1.70%), Bionex (1.60%), and Prestige Biopharma (1.49%) also retreated together.

■ Large-Cap Bio Stocks Celltrion closed down 0.68% at 174,500 won, and Celltrion Pharm fell 0.62% to 39,850 won. Celltrion's trading volume was 727,087 shares, the highest among the stocks included in the data.

Today's movement is interpreted as showing a differentiated pattern driven by stock-specific supply and demand, rather than the entire bio-pharmaceutical sector moving in one direction.

[※ This article was written based on provided market price data and is not intended to solicit investment. Investment decisions and responsibilities lie with the investor. This article was written with AI assistance.]